Teva Pharmaceuticals Industries Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Teva Pharmaceuticals Industries Ltd. - overview
Established
1901
Location
Tel Aviv, -, Israel
Primary Industry
Pharmaceuticals
About
Teva Pharmaceuticals Industries Ltd. is a prominent global pharmaceutical company specializing in innovative biopharmaceuticals and a comprehensive range of generic medications. The firm is dedicated to improving patient access to healthcare solutions worldwide. Teva Pharmaceuticals Industries Ltd.
founded in 1901 and headquartered in Tel Aviv, Israel, focuses on manufacturing and distributing pharmaceutical products. The company has undergone various strategic shifts to enhance its product offerings. Eliezer Ben-Moshe established the firm, which has since evolved into a leader in both generics and innovative therapeutics under the leadership of CEOs Fa Kemi, Jelena Livsica, and Paul Anderson. In March 2026, Blackstone invested in the company.
Teva Pharmaceuticals Industries Ltd. specializes in a diverse array of products, including both innovative biopharmaceuticals and established generics. Their core offerings encompass prescription medications for therapeutic areas such as neurology, oncology, and respiratory conditions. Notable products include AJOVY® (fremanezumab) for migraine prevention and Saxenda® (liraglutide injection) for weight management.
The company invests significantly in research and development, aiming to create new treatments while maintaining a robust portfolio of generic medications that enhance patient access to affordable healthcare solutions. In 2023, Teva Pharmaceuticals Industries Ltd. reported a revenue of USD 15. 84 bn, with an EBITDA of USD 1.
59 bn. The company generates revenue through the sale of prescription medications and engages in B2B transactions with healthcare providers and pharmacies, leveraging its extensive product portfolio. Teva Pharmaceuticals Industries Ltd. plans to launch new products in the coming years, focusing on expanding its innovative drug offerings and generic medications.
The company is targeting growth in emerging markets, including regions in Asia and Latin America, with plans to establish a stronger presence by 2025. Recent funding will be allocated to enhance research and development initiatives and to support marketing efforts for new product launches.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.tevapharm.com
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Teva Pharmaceuticals Industries Ltd. - timeline of key events
Teva Pharmaceuticals Industries Ltd. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 18,312,000,000 | 20,317,000,000 | 20,314,000,000 | 20,272,000,000 | 19,652,000,000 | 21,903,000,000 | 22,385,000,000 | 18,854,000,000 | 16,887,000,000 | 16,659,000,000 | 15,878,000,000 | 14,925,000,000 | - | - | - |
| % Revenue Growth (YoY) | - | 10.9% | (0.0%) | (0.2%) | (3.1%) | 11.5% | 2.2% | (15.8%) | (10.4%) | (1.4%) | (4.7%) | (6.0%) | - | - | - |
| EBITDA (USD) | 4,178,000,000 | 3,913,000,000 | 3,291,000,000 | 5,459,000,000 | 4,660,000,000 | 3,678,000,000 | (15,372,000,000) | 205,000,000 | 1,279,000,000 | (2,015,000,000) | 3,046,000,000 | (791,000,000) | - | - | - |
| Operating Income (USD) | 3,109,000,000 | 2,205,000,000 | 1,649,000,000 | 3,951,000,000 | 3,352,000,000 | 2,154,000,000 | (17,484,000,000) | (1,637,000,000) | (443,000,000) | (3,572,000,000) | 1,716,000,000 | (2,099,000,000) | - | - | - |
| Operating Margin | 17.0% | 10.9% | 8.1% | 19.5% | 17.1% | 9.8% | (78.1%) | (8.7%) | (2.6%) | (21.4%) | 10.8% | (14.1%) | - | - | - |
| % EBITDA Margin | 22.8% | 19.3% | 16.2% | 26.9% | 23.7% | 16.8% | (68.7%) | 1.1% | 7.6% | (12.1%) | 19.2% | (5.3%) | - | - | - |
| NET Income (USD) | 2,768,000,000 | 1,910,000,000 | 1,253,000,000 | 3,042,000,000 | 1,597,000,000 | 311,000,000 | (16,449,000,000) | (2,472,000,000) | (1,000,000,000) | (4,099,000,000) | 456,000,000 | (2,406,000,000) | - | - | - |
| % Net Margin | 15.1% | 9.4% | 6.2% | 15.0% | 8.1% | 1.4% | (73.5%) | (13.1%) | (5.9%) | (24.6%) | 2.9% | (16.1%) | - | - | - |
Teva Pharmaceuticals Industries Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Announced | Emalex Biosciences, Inc. | - | ||||||||
| PIPE | Announced | Teva Pharmaceuticals Industries Ltd. | - | ||||||||
| Add-on | Completed | Plan B One-Step | - | ||||||||
| Add-on | Completed | Take Action | - | ||||||||
| Add-on | Completed | Aftera | - |
Displaying 1 - 5 of 9
Teva Pharmaceuticals Industries Ltd. - employee data
Teva Pharmaceuticals Industries Ltd. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman of the Board | BM | ||||||
| Chairman Business Advisory Board | BM | ||||||
| Chairman Of The Board at Lumenis | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.